Jade Biosciences, Inc. (NASDAQ: JBIO) announced the dosing of the first participant in its Phase 2 JUNIPER clinical trial on May 26, 2026. This essential…
Plus Therapeutics, Inc. (NASDAQ: PSTV) recently announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead radiotherapeutic. This milestone…
March 16, 2026
NeuroSense Therapeutics Breakthrough: PrimeC Shows 43% Survival Benefit in Peer-Reviewed ALS Study
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) recently secured a major scientific validation for its lead drug candidate, PrimeC. The company announced the peer-reviewed publication of its…
February 26, 2026
Vanda Secures FDA Review for Potential GPP Breakthrough
Vanda Pharmaceuticals (NASDAQ: VNDA) recently reached a significant regulatory milestone regarding its rare disease pipeline expansion. The U.S. Food and Drug Administration (FDA) has officially…
February 24, 2026
Edesa Biotech Shares Fly; Successful Phase 3 ARDS Results
Edesa Biotech (NASDAQ: EDSA) witnessed a significant surge in its share price during the most recent trading session. This volatility followed the release of positive…
February 23, 2026
Gossamer Bio Fails Stringent Trial Thresholds in 80% Wipeout
Gossamer Bio, Inc. (NASDAQ: GOSS) experienced a catastrophic 80% decline in its share price during early Monday trading. This massive sell-off follows the announcement that…
February 19, 2026
Moleculin Sacrifices Share Price for Clinical Runway
Moleculin Biotech, Inc. (NASDAQ: MBRX) experienced a sharp decline in its share price on the Nasdaq Capital Market following a strategic financing announcement. This significant…
January 28, 2026
Immix Biopharma Secures Pivotal FDA Breakthrough Status
Immix Biopharma (NASDAQ: IMMX) recently secured a strategic regulatory win that has significantly altered the company’s investment profile. The company announced that the FDA granted…
January 22, 2026
Lexicon Pharmaceuticals Secures FDA Alignment for LX9211
Lexicon Pharmaceuticals (NASDAQ: LXRX) recently announced a major regulatory milestone regarding its lead clinical candidate, LX9211. The company successfully completed an End-of-Phase 2 meeting with…
May 07, 2025
Alzamend Neuro Taps AI Imaging Partner QMENTA for Phase II AL001 Trials at Massachusetts General
Alzamend Neuro (NASDAQ: ALZN), a clinical-stage biotech company focused on treatments for Alzheimer’s and other neurological conditions, has announced a strategic collaboration with QMENTA, an…